Overview

A Study to Evaluate AZP531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus

Status:
Unknown status
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Objectives: Primary Objectives - To investigate the safety and tolerability of single ascending doses of AZP- 531 in healthy volunteers. - To investigate the safety and tolerability of single and multiple ascending doses of AZP-531 in overweight/obese volunteers. - To investigate the safety and tolerability of single and multiple ascending doses of AZP-531 in patients with type 2 diabetes mellitus. Secondary Objectives • To determine the plasma pharmacokinetic (PK) profile of AZP-531 after single and multiple doses. Exploratory Objectives • To obtain exploratory data on the effects of AZP-531 on the pharmacodynamic (PD) markers of blood glucose, interstitial glucose, insulin, and plasma acylated ghrelin (AG) and unacylated ghrelin (UAG)
Phase:
Phase 1
Details
Lead Sponsor:
Alizé Pharma